A
A

Amgen


Nieuws

Cigna expects revenue gains from launches of Humira biosimilars

UPDATE 2-Cigna expects revenue gains from launches of Humira biosimilars Rewrites, adds management and analyst comments, updates shares By Leroy Leo Feb 3 (Reuters) - Cigna Corp CI.N expects its pharmacy benefit management unit to earn more from the second half of 2023 as makers of cheaper versions of AbbVie Inc's ABBV.N arthritis drug Humira will boost aftermarket discounts to gain access to patients.
A
C

Amgen's Tezspire gets FDA Approval For Self-Administration For Patients With Severe Asthma

BRIEF-Amgen's Tezspire gets FDA Approval For Self-Administration For Patients With Severe Asthma Feb 2 (Reuters) - Amgen Inc AMGN.O : AMGEN - ANNOUNCED FDA APPROVED TEZSPIRE FOR SELF-ADMINISTRATION IN PRE-FILLED, SINGLE-USE PEN FOR PATIENTS AGED 12 YEARS & OLDER WITH SEVERE ASTHMA AMGEN INC - FDA HAS APPROVED TEZSPIRE FOR SELF-ADMINISTRATION IN U.S
A
A

AbbVie's Humira gets a U.S. rival, but costs could stay high

FOCUS-AbbVie's Humira gets a U.S. rival, but costs could stay high Updates to clarify lower price may not be widely used, rather than widely available, and why By Patrick Wingrove Jan 31 (Reuters) - U.S. patients will finally get access to cheaper versions of AbbVie Inc’s ABBV.N blockbuster arthritis drug Humira this year, but the cost savings are expected to be limited.
A
C

Wall St falls as Fed decision looms; AMD boosts chipmakers

US STOCKS-Wall St falls as Fed decision looms; AMD boosts chipmakers For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window. Fed's rate decision expected at 1400 ET AMD expects strong second half of 2023 Amgen weighs on Dow as Q4 revenue falls slightly EA cuts bookings view, shares slide Indexes down: Dow 1.12%, S&P 0.63%, Nasdaq 0.44% Adds comments, details; updates prices By Johann M Cherian and Shreyashi Sanyal Feb 1 (Reuters) - U.S.
A
F
A
E
U
U

U.S. STOCKS Synchrony Financial, Moody's Corp, Funko, Mondelez

BUZZ-U.S. STOCKS ON THE MOVE-Synchrony Financial, Moody's Corp, Funko, Mondelez Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 U.S. stock indexes fell on Wednesday ahead of the Federal Reserve's decision on interest rates later in the day, while an upbeat outlook from Advanced Micro Devices lifted chipmakers.
A
A
B
C
C
M
M
T
A
W
E
J
U
U
S
T
W
R

Wall St dips as Fed decision looms; AMD boosts chipmakers

US STOCKS-Wall St dips as Fed decision looms; AMD boosts chipmakers For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window. Fed's rate decision expected at 1400 ET AMD expects strong second half of 2023 Amgen weighs on Dow as Q4 revenue falls slightly EA cuts bookings view, shares slide Indexes down: Dow 0.64%, S&P 0.26%, Nasdaq 0.15% Updates prices to open, adds details By Johann M Cherian and Shreyashi Sanyal Feb 1 (Reuters) - U.S.
A
F
A
E
U
U

U.S. STOCKS Tesla, Peloton, Thermo Fisher Scientific

BUZZ-U.S. STOCKS ON THE MOVE-Tesla, Peloton, Thermo Fisher Scientific Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 U.S. stock indexes were set to open lower on Wednesday as investors cautiously awaited the Federal Reserve's decision on interest rates later in the day, while chipmaker Advanced Micro Devices climbed on an upbeat outlook.
A
A
B
C
C
D
M
M
T
A
W
E
T
U
S
T

Wall St set to open lower ahead of Fed decision; AMD rises on outlook

US STOCKS-Wall St set to open lower ahead of Fed decision; AMD rises on outlook For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window. Fed's rate decision expected at 1400 ET AMD expects strong second half of 2023 Amgen slips as Q4 revenue falls slightly EA cuts bookings view, shares slide Social media stocks slip on Snap's warnings Futures off: Dow 0.40%, S&P 0.24%, Nasdaq 0.07% Updates prices, adds comments, details By Johann M Cherian and S
A
F
G
I
A
E
U
U
U

Futures dip on jitters ahead of ADP report, Fed decision

US STOCKS-Futures dip on jitters ahead of ADP report, Fed decision For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window. Fed's rate decision expected at 1400 ET AMD expects strong second half of 2023 Amgen slips as Q4 revenue falls slightly EA cuts bookings view, shares slide Platform providers slip on Snap's warnings Futures: Dow down 0.36%, S&P off 0.18%, Nasdaq flat By Johann M Cherian Feb 1 (Reuters) - U.S.
A
F
G
I
A
E
U
U
U

Beigene Will Retain Anthony C. Hooper

BRIEF-Beigene Will Retain Anthony C. Hooper Jan 31 (Reuters) - Beigene Ltd 6160.HK : BEIGENE - ON JAN 30, AMGEN ELECTED TO RELINQUISH ITS RIGHT TO APPOINT A DESIGNATED DIRECTOR TO COMPANY'S BOARD OF DIRECTORS BEIGENE - CO WILL RETAIN ANTHONY C. HOOPER Further company coverage: 6160.HK
A

Amgen revenue falls slightly as Lilly COVID deal contributes less

UPDATE 1-Amgen revenue falls slightly as Lilly COVID deal contributes less Adds FTC information request, share move By Sriparna Roy and Michael Erman Jan 31 (Reuters) - Amgen Inc AMGN.O on Tuesday said its fourth-quarter revenue fell slightly as a 4% increase in sales of its own drugs was offset by lower revenue from its deal to manufacture COVID-19 antibody treatments for Eli Lilly and Co.
A

Amgen - QTRLY Earnings Per Share $3.00; QTRLY Adjusted Earnings Per Share $4.09

BRIEF-Amgen - QTRLY Earnings Per Share $3.00; QTRLY Adjusted Earnings Per Share $4.09 Jan 31 (Reuters) - Amgen Inc AMGN.O : AMGEN - QTRLY TOTAL PRODUCT SALES UP 4% AMGEN - QTRLY EARNINGS PER SHARE $3.00; QTRLY ADJUSTED EARNINGS PER SHARE $4.09 AMGEN INC Q4 EARNINGS PER SHARE VIEW $4.10, REVENUE VIEW $6.77 BILLION -- REFINITIV IBES DATA AMGEN - QTRL
A

Amgen revenue falls slightly as Lilly COVID deal contributes less

Amgen revenue falls slightly as Lilly COVID deal contributes less Jan 31 (Reuters) - Amgen Inc AMGN.O on Tuesday said its fourth-quarter revenue fell slightly as a 4% increase in sales of its own drugs was offset by lower revenue from its deal to manufacture COVID-19 antibody treatments for Eli Lilly and Co. LLY.N Amgen reported revenue of $6.84 billion in the quarter, down from $6.85 billion a year ago, but ahead of analysts' estimates of $6.77 billion, according to Refinitiv data.
A

Amgen launches biosimilar version of AbbVie's Humira

UPDATE 1-Amgen launches biosimilar version of AbbVie's Humira Adds analysts quote By Khushi Mandowara Jan 31 (Reuters) - Amgen Inc AMGN.O said on Tuesday it launched a biosimilar version of AbbVie Inc's ABBV.N big selling arthritis treatment, the first such competition for Humira in the United States. Amgen said i ts drug, Amjevita, or adalimumab-atto, will have two list prices -- $3,288 and $1,557 per 40 milligram pen device for a two-week supply -- representi ng a discount of 5% a nd 55% to Hu
A

AbbVie's Humira gets a U.S. rival, but costs could stay high

FOCUS-AbbVie's Humira gets a U.S. rival, but costs could stay high Updates with new CVS policy By Patrick Wingrove Jan 31 (Reuters) - U.S. patients will finally get access to cheaper versions of AbbVie Inc’s ABBV.N blockbuster arthritis drug Humira this year, but the cost savings are expected to be limited. Rival drugmaker Amgen Inc AMGN.O on Tuesday launched Amjevita, the first biosimilar version of AbbVie’s 20-year-old drug, with two tiers of pricing.
A
C

Amgen Says Amjevita (Adalimumab-Atto), A Biosimilar To Humira (Adalimumab), Is Now Available In U.S.

BRIEF-Amgen Says Amjevita (Adalimumab-Atto), A Biosimilar To Humira (Adalimumab), Is Now Available In U.S. Jan 31 (Reuters) - Amgen Inc AMGN.O : AMGEN - AMJEVITA (ADALIMUMAB-ATTO), A BIOSIMILAR TO HUMIRA (ADALIMUMAB), IS NOW AVAILABLE IN U.S. AMGEN - AMJEVITA IS ALSO AVAILABLE AT LIST PRICE 5% BELOW CURRENT HUMIRA LIST PRICE AMGEN - AMJEVITA (40 MG
A

AbbVie's Humira gets a U.S. rival, but costs could stay high

FOCUS-AbbVie's Humira gets a U.S. rival, but costs could stay high By Patrick Wingrove Jan 31 (Reuters) - U.S. patients will finally get access to cheaper versions of AbbVie Inc’s ABBV.N blockbuster arthritis drug Humira this year, but the cost savings are expected to be limited. Rival drugmaker Amgen Inc AMGN.O on Tuesday launched Amjevita, the first biosimilar version of AbbVie’s 20-year-old drug, with two tiers of pricing.
A
C

Amgen launches biosimilar version of AbbVie's Humira

Amgen launches biosimilar version of AbbVie's Humira NEW YORK, Jan 31 (Reuters) - Amgen Inc AMGN.O on Tuesday said it was launching Amjevita, or adalimumab-atto, a biosimilar version of AbbVie Inc's ABBV.N big selling arthritis treatment Humira, the first such biosimilar competition for the drug in the United States. Amgen said the drug will have two list prices that represent a discount of either 5% or 55% to Humira, depending on who is doing the purchasing.
A

'Soft landing' or 'no landing'?

MORNING BID-'Soft landing' or 'no landing'? A look at the day ahead in U.S. and global markets from Mike Dolan There's an uncomfortable feeling in markets this week that good news may be bad news once again - mainly because of what the former means for this week's big central banking set pieces. As U.S. Federal Reserve's Federal Open Market Committee kicks off its two-day policymaking meeting, the economic news from around the world brightened considerably.
A
A
A
G
M
P
U
U
A
W
E
J
U
U
S
S
A
P

Amgen Announces Organizational Changes

BRIEF-Amgen Announces Organizational Changes Jan 30 (Reuters) - Amgen Inc AMGN.O : AMGEN - RECENTLY ANNOUNCED ORGANIZATIONAL CHANGES, MAINLY IN COMMERCIAL TEAM, THAT HAVE LED TO DISPLACEMENT OF ABOUT 300 TEAM MEMBERS BASED IN U.S. Further company coverage: AMGN.O
A



Voorwaarden

Populaire activa

Disclaimer: De entiteiten van de XM Group bieden diensten en toegang tot ons online handelsplatform op basis van uitsluitend-uitvoering, waardoor een persoon de beschikbare content op of via de website kan bekijken en/of gebruiken, zonder dat dit is bedoeld voor wijziging of uitbreiding. Dergelijk(e) toegang en gebruik vallen onder: (i) de algemene voorwaarden; (ii) risicowaarschuwingen; en de (iii) volledige disclaimer. Dergelijke content wordt daarom alleen aangeboden als algemene informatie. Wees u er daarnaast vooral van bewust dat de inhoud op ons online handelsplatform geen verzoek of aanbieding omvat om transacties op de financiële markten uit te voeren. Het beleggen op welke financiële markt dan ook vormt een aanzienlijk risico voor uw vermogen.

Alle materialen die op ons online handelsplatform worden gepubliceerd zijn bedoeld voor educatieve/informatieve doeleinden en omvatten geen – en moeten niet worden beschouwd als het bevatten van – financieel, vermogensbelastings- of handelsadvies en aanbevelingen, of een overzicht van onze handelsprijzen, of een aanbod of aanvraag van een transactie in financiële instrumenten of ongevraagde financiële promoties voor u.

Alle content van derden, alsmede content die is voorbereid door XM, zoals opinies, nieuws, onderzoeken, analyses, prijzen en andere informatie of koppelingen naar externe websites op deze website worden aangeboden op een 'zoals-ze-zijn'-basis, als algemene marktcommentaren, en vormen geen beleggingsadvies. Voor zover dat content wordt beschouwd als beleggingsonderzoek, moet u zich ervan bewust zijn en accepteren dat de content niet bedoeld was en niet is voorbereid in overeenstemming met de wettelijke vereisten die zijn opgesteld om de onafhankelijkheid van beleggingsonderzoek te bevorderen en als zodanig onder de geldende wetgeving en richtlijnen moet worden beschouwd als marketingcommunicatie. Zorg ervoor dat u onze Mededeling over niet-onafhankelijk beleggingsonderzoek en risicowaarschuwing in verband met de voorgaande informatie doorneemt en begrijpt; die kunt u hier lezen.

We gebruiken cookies om u de beste ervaring op onze website te bieden. Meer lezen of wijzig uw cookie-instellingen.

Risicowaarschuwing: Uw vermogen loopt risico. Hefboomproducten zijn mogelijk niet voor iedereen geschikt. Lees onze informatie over risico's.